GOlDiLOX, an investigator-initiated clinical trial
GOlDiLOX: A World-First Combination
Prof. Cheah and a clinical trial patient
“This is the study everyone in the world would like to be doing, and we have delivered it to Australian patients first. We’re incredibly excited to have this investigator-initiated trial open in Perth and Melbourne, with many other sites around Australia to follow. Studies like this demonstrate that Australia is at the forefront of lymphoma research globally and give patients unprecedented access to potentially lifesaving therapies,”
– Professor Chan Cheah
In a significant stride toward combating Mantle Cell Lymphoma (MCL), a partnership between Professor Chan Cheah and Professor Michael Dickinson at Peter MacCallum Cancer Centre in Melbourne has pioneered this highly anticipated clinical trial, GOlDiLOX. This investigator-initiated trial merges two of the most active drugs for MCL treatments: Pirtobrutinib, an oral tablet, and Glofitamab, a monoclonal antibody. While these two types of treatments are not commercially available in Australia, they have been shown to be extremely effective in mantle cell lymphoma patients resistant to current approved therapies.
GOlDiLOX offers far more than just a research study; it extends a lifeline to 36 patients nationwide, providing an unparalleled opportunity to combat MCL years before these treatments would typically become available. For some patients, time is of the essence, and waiting years for treatment is not an option.
Through initiatives like GOlDiLOX, Australia remains at the forefront of global lymphoma research. This dedication to innovative trials not only advances medical science but also nurtures hope in patients grappling with the challenges of MCL. This is research brought to life—a beacon of hope lighting the path toward a future where blood cancer is conquerable, and lives are transformed.
For more information and specifics about GOlDiLOX, visit the Trial Page Here
Support us at Blood Cancer Research
Each year, 20,000 Australians are diagnosed with blood cancer. By 2035, blood cancer will be the leading cause of death from cancer. The fastest way to get better treatments to blood cancer patients is to offer them a clinical trial, however, the resources required to run trials are immense.
Blood Cancer Research Western Australia was established in 2016 when Professor Chan Cheah returned to WA and noticed there was only 3 trials available to blood cancer patients. In the few years since Professor Cheah launched the idea of Blood Cancer Research WA, we are proud to say we offer over 107 lifesaving trials to the 864 patients we currently care for. We have also started launching home grown trials, created by our incredible team and that are now available internationally.
With your support, we can help fund our dedicated fellows and nurses as they facilitate crucial clinical trials and offer groundbreaking treatments to patients that need it here in WA.
Your support and any contribution to help our mission is greatly appreciated.